SG11202007072RA - Chemokine receptor modulators and uses thereof - Google Patents

Chemokine receptor modulators and uses thereof

Info

Publication number
SG11202007072RA
SG11202007072RA SG11202007072RA SG11202007072RA SG11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA
Authority
SG
Singapore
Prior art keywords
chemokine receptor
receptor modulators
modulators
chemokine
receptor
Prior art date
Application number
SG11202007072RA
Other languages
English (en)
Inventor
Jeffrey J Jackson
John Michael Ketcham
Akinori Okano
Maureen Kay Reilly
Omar Robles-Resendiz
Jacob Bradley Schwarz
Parcharee Tivitmahaisoon
David Juergen Wustrow
Ashkaan Younai
Mikhail Zibinsky
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66286951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202007072R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of SG11202007072RA publication Critical patent/SG11202007072RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11202007072RA 2018-01-26 2019-01-24 Chemokine receptor modulators and uses thereof SG11202007072RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862622771P 2018-01-26 2018-01-26
US201862772027P 2018-11-27 2018-11-27
US201862784161P 2018-12-21 2018-12-21
PCT/US2019/015023 WO2019147862A1 (en) 2018-01-26 2019-01-24 Chemokine receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
SG11202007072RA true SG11202007072RA (en) 2020-08-28

Family

ID=66286951

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007072RA SG11202007072RA (en) 2018-01-26 2019-01-24 Chemokine receptor modulators and uses thereof

Country Status (14)

Country Link
US (4) US10683280B2 (zh)
EP (1) EP3743418A1 (zh)
JP (2) JP7355758B2 (zh)
KR (1) KR20200125932A (zh)
CN (1) CN111971279A (zh)
AU (1) AU2019212478C1 (zh)
BR (1) BR112020015056A2 (zh)
CA (1) CA3089380A1 (zh)
IL (1) IL276295B2 (zh)
MX (1) MX2020007812A (zh)
RU (1) RU2020128176A (zh)
SG (1) SG11202007072RA (zh)
TW (1) TWI826416B (zh)
WO (1) WO2019147862A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971279A (zh) 2018-01-26 2020-11-20 拉普特医疗公司 趋化因子受体调节剂及其用途
TW202200560A (zh) 2020-04-30 2022-01-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
CN111732572B (zh) * 2020-07-31 2020-11-13 苏州国匡医药科技有限公司 一种手性抗肿瘤药物flx475及其中间体的制备方法
JP2024505561A (ja) 2021-02-02 2024-02-06 ラプト・セラピューティクス・インコーポレイテッド Ｇタンパク質共役型受容体モジュレーターのトランス異性体形態を調製する方法
CN115466244A (zh) * 2021-06-10 2022-12-13 武汉伯瑞恒医药科技有限公司 趋化因子受体ccr4拮抗剂、其中间体、制备方法、药物组合物和应用
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
WO2023072924A1 (en) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
TW202325271A (zh) 2021-10-28 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
WO2023143194A1 (zh) * 2022-01-25 2023-08-03 瑞石生物医药有限公司 一种ccr4小分子拮抗剂及其用途
WO2023196432A1 (en) * 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
TW202411219A (zh) * 2022-06-02 2024-03-16 大陸商西藏海思科製藥有限公司 雜環化合物ccr4抑制劑及其用途
CN118084893A (zh) * 2022-11-28 2024-05-28 上海美悦生物科技发展有限公司 杂环取代的嘧啶类化合物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
AU2001266232B2 (en) 2000-07-07 2005-09-15 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
TW200800167A (en) 2002-03-15 2008-01-01 Novartis Ag Organic compounds
JP5067364B2 (ja) * 2006-03-24 2012-11-07 アステラス製薬株式会社 アシルアミノピペリジン化合物
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
MA33132B1 (fr) 2009-02-26 2012-03-01 Glaxo Group Ltd Derives pyrazole utilises comme antagonistes du recepteur ccr4
EP4036088B1 (en) 2010-03-10 2024-04-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2013082429A1 (en) * 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
MX2019001223A (es) * 2016-07-29 2019-11-11 Flx Bio Inc Moduladores de receptores de quimioquina y usos de los mismos.
AU2018360766A1 (en) * 2017-11-06 2020-05-21 Rapt Therapeutics, Inc. Anticancer agents
CN111971279A (zh) 2018-01-26 2020-11-20 拉普特医疗公司 趋化因子受体调节剂及其用途

Also Published As

Publication number Publication date
EP3743418A1 (en) 2020-12-02
AU2019212478A1 (en) 2020-08-06
RU2020128176A (ru) 2022-03-02
US20190233397A1 (en) 2019-08-01
JP7355758B2 (ja) 2023-10-03
IL276295A (en) 2020-09-30
MX2020007812A (es) 2020-11-24
US11384064B2 (en) 2022-07-12
IL276295B2 (en) 2024-02-01
TWI826416B (zh) 2023-12-21
KR20200125932A (ko) 2020-11-05
US10683280B2 (en) 2020-06-16
JP2023179513A (ja) 2023-12-19
JP2021512152A (ja) 2021-05-13
WO2019147862A1 (en) 2019-08-01
BR112020015056A2 (pt) 2020-12-08
IL276295B1 (en) 2023-10-01
US20200325117A1 (en) 2020-10-15
TW201945356A (zh) 2019-12-01
US20230139321A1 (en) 2023-05-04
US11192879B2 (en) 2021-12-07
CA3089380A1 (en) 2019-08-01
AU2019212478B2 (en) 2023-02-23
AU2019212478C1 (en) 2023-11-16
CN111971279A (zh) 2020-11-20
US20200339539A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
IL276295A (en) Modulators of chemokine receptors and their uses
ZA201900961B (en) Chemokine receptor modulators and uses thereof
ZA201807731B (en) Spiro-lactam nmda receptor modulators and uses thereof
IL276332A (en) Spiro-lactam NMDA receptor modulators and their use
IL276330A (en) Spiro-lactam NMDA receptor modulators and their use
IL272599A (en) Pyruvate kinase modulators and their use
IL264514B (en) Spiro-lactam nmda receptor modulators and their uses
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3490994C0 (en) SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND THEIR USE
ZA202105847B (en) Mtroc modulators and uses thereof
IL292923B2 (en) CXCR4 cytokine receptor modulators and related uses
DK3830092T3 (en) Heteroaromatic nmda receptor modulators and uses thereof
ZA201905513B (en) Rorgamma modulators and uses thereof
ZA201905511B (en) Rorgamma modulators and uses thereof